TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tolperisone in Acute Muscle Spasm of the Back

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory~* Current acute back pain and/or stiffness due to acute and painful muscle spasm starting within 7 days prior to study entry and more than 8 weeks after the last episode of acute back pain.~* Pain of 4 or more on the subject right now rating of pain intensity Numeric Rating Scale (NRS) scale of 0-10.~* Willing to discontinue all medication used for the treatment of pain or muscle spasm on study entry.~* Pain localized below the neck and above the inferior gluteal folds.~* Body mass index ranging between 18 and 35 kg/m².~Exclusion Criteria:~* Unwillingness to stop taking pain or antispasmodic medication other than the study medication (specifically opioid use \[e.g., Vicodin\], barbiturates, and cannabis).~* Chronic pain for the previous 3 months or longer, on more days than not.~* Radicular pain in the lower extremity (i.e. pain radiating below the knee), sciatica pain down the leg, or pain below the knee (indicating a lumber radiculopathy); radicular pain in the upper extremity, radiating into the forearm or hand (indicating a cervical radiculopathy).~* Concomitant severe pain in a region other than the back.~* Spinal surgery within 1 year of study entry.~* Back pain due to major trauma (e.g., motor vehicle accident, fracture of bone) unless resolved for more than 1 year.~* Treatment of back pain ongoing with non-pharmacological therapy (e.g., acupuncture, chiropractic adjustment, massage, Transcutaneous Electrical Nerve Stimulation \[TENS\], physiotherapy).~* Subjects who test positive for alcohol by breathalyzer test.~* Unwilling to stop taking moderate to potent inhibitors of cytochrome P450 (CYP) isozymes CYP2D6 and CYP2C19, which are likely to cause drug interactions with tolperisone HCl (e.g., medications such as paroxetine and fluvoxamine).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tolperisone 50 mg (Type: EXPERIMENTAL): TID (150 mg/day)
- Tolperisone 100 mg (Type: EXPERIMENTAL): TID (300 mg/day)
- Tolperisone 150 mg (Type: EXPERIMENTAL): TID (450 mg/day)
- Tolperisone 200 mg (Type: EXPERIMENTAL): TID (600 mg/day)
- Placebo (Type: PLACEBO_COMPARATOR): TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of nasopharyngeal carcinoma~* Distance metastasis at least 6 months after radical treatment~* Not suitable for local treatment, e.g. surgery, TACE~* At least one measurable lesion~* Estimate survival \>3months~* Range from 18～70 years old~* PS 0\~1~* WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L~* ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN~* 0Serum creatinine \< 1.5×ULN~Exclusion Criteria:~* Central nervous system metastases~* Suitable for local treatment~* Second malignancy within 5 years~* Precious therapy with an investigational agent~* Uncontrolled seizure disorder or other serious neurologic disease~* ≥ Grade Ш allergic reaction to any drug including in this study~* Clinically significant cardiac or respiratory disease~* Creatinine clearance \< 30ml/min~* Drug or alcohol addition~* Do not have full capacity for civil acts~* Severe complication, active infection~* Concurrent immunotherapy or hormone therapy for other diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PF+ Nimotuzumab (Type: EXPERIMENTAL): Patients treated with cisplatin and 5-Fu combined with nimotuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Admission to the intensive care unit for ≥ 72 hours and expected to stay an additional 48 hours~* IV access for administration of study drug~* Subject (or subject's legal representative) able to give written informed consent~Exclusion Criteria:~* History of hypersensitivity or intolerance to echinocandin antifungals~* Liver function test (ALT, AST (aspartate aminotransferase), and/or total bilirubin) greater than 10 times the upper limits of normal (ULN)~* Pregnant or lactating women~* Treatment with systemic antifungal therapy within the preceding 7 days~* Documented invasive fungal infection at baseline/screening~* Life expectancy less than 2 days or moribund

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Standard care/empiric therapy group
- 1 (Type: EXPERIMENTAL): Active surveillance/ preemptive therapy group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Participants who met the following main selection criteria were included in the study.~Inclusion Criteria:~* Histologically or cytologically proven adenocarcinoma of the colon or rectum~* Metastatic disease that is not amenable to potentially curative treatment~* One and only one prior line of treatment for metastatic disease. This prior line should be an oxaliplatin based chemotherapy (participants who relapse within 6 months of completion of oxaliplatin based adjuvant chemotherapy are eligible)~* Prior treatment with bevacizumab is permitted.~Exclusion Criteria:~* Prior therapy with irinotecan~* Eastern Cooperative Oncology Group performance status \>2~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/FOLFIRI (Type: PLACEBO_COMPARATOR): Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
- Aflibercept/FOLFIRI (Type: EXPERIMENTAL): Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibromyalgia Health Outcome Study on Cost of Treatments

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet criteria for fibromyalgia (FM) in the opinion of the investigator~* Must be prescribed a 'new' treatment for FM~* Male and female participants at least 18 years of age~* Willing to complete the Informed Consent Document (ICD) and any other required forms to be eligible for study participation~* Currently under the care of the participating physician~* Cognitively able to understand and complete participant self-rated scales in English or Spanish via computer-assisted telephone interview (CATI)~* Available for 12 months to participate in the study~Exclusion Criteria:~* Are investigator site personnel directly affiliated with the study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted~* Are Lilly employees~* Are Terminally ill~* Currently participating in other research studies or if beginning a research study while participating in this study~* Unable to respond via telephone for CATI~* Incompetent for interview as deemed by the participating physician~* Unwilling to provide written ICD or other required forms to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibromyalgia (FM) Participants (Type: None): FM participants starting any new pharmacologic FM agent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Written informed consent has been obtained~  * Males and females, at least 18 years of age~ * History of IC/PBS for at least 6 months documented in the medical record~ * Recurring IC/PBS symptoms~ * An average of 8 or more urine voids over a 3-day period, confirmed by the baseline voiding diary~ * Bladder pain score \> 4 in the last 24 hours (assessed at screening visit)~ * Previous use of medications and/or treatment(s) for symptom relief~ * Females of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives (birth control pills)) during the 4 week course of therapy and 1 week thereafter~ * Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the voiding diaries and self-administered questionnaires~Exclusion Criteria:~* • Subjects currently taking prescribed medications for IC/PBS will be able to continue the medications throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded.~  * Subjects must not have had intravesical treatment(s)/bladder installations of the following medications: dimethylsulfoxide (DMSO), lidocaine and/or heparin within 1 month prior to study visit 1~ * Pregnant or lactating~ * History of bleeding diathesis~ * Currently on anticoagulant therapy (e.g. warfarin, clopidogrel)~ * Active bleeding peptic ulcer disease~ * Obvious neurological impairment which may be affecting bladder function~ * Known allergy to liposomes and/or egg yolk~ * Current or previous participation in another therapeutic or device study within 6 months of the screening visit~ * The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomes (Type: EXPERIMENTAL): Liposomes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven resectable stage II or III adenocarcinoma of the stomach~* No evidence of locally inoperable or distant metastases on chest x-ray and any combination of abdominal ultrasound, CT scan, or laparoscopy~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* WHO 0-1~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Creatinine clearance greater than 60 mL/min~Cardiovascular:~* No clinical evidence of uncontrolled angina pectoris, cardiac failure, or significant uncontrolled cardiac arrhythmia~Other:~* No medical contraindication to study therapy~* No other prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix~* Not pregnant~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with confirmed or suspected clear cell Renal cell carcinoma;~* 68Ga-P16-093 18F-FDG PET/CT within a week;~* signed written consent.~Exclusion Criteria:~* pregnancy;~* breastfeeding;~* known allergy against PSMA;~* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-P16-093 and 18F-FDG PET/ CT scan (Type: EXPERIMENTAL): Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject 18-70 years of age~* Subject agrees to refrain from taking any opioid medications other than study medication during study period.~* History of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline~Exclusion Criteria:~* Subject has a documented history of allergic reaction or clinically significant intolerance to morphine or other opioids, such that treatment with morphine is contraindicated.~* Subject is pregnant or breast-feeding.~* Subject is receiving chemotherapy, or has an active malignancy of any type or has been diagnosed with cancer within the past three years (excluding squamous or basal cell carcinoma of the skin).~* Subject has a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit.~* Subject has a Body Mass Index (BMI)\>45kg/m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALO-01 (Type: EXPERIMENTAL): Doses given once or twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Ages greater than or equal to18 years and less than or equal to 50 years~Normal renal function: creatinine less than 1.5 mg/dl~Normal liver function: total bilirubin less than 1.5mg/dl, ALT and AST levels must be below the laboratory's high normal value.~Normal blood count:~WBC 3000-10000/mm(3)~Granulocytes greater than 1500/mm(3)~Platelets greater than 150,000/mm(3), and~Hemoglobin (females greater than 11.1 g/dl, males greater than 12.7 g/dl)~Antecubital veins must be adequate for peripheral access for phlebotomy (subject must be eligible for normal blood donation)~Ability to comprehend the investigational nature of the study and provide informed consent~EXCLUSION CRITERIA: ANY OF THE FOLLOWING:~Active infection or history of recurrent infection, hepatitis B and C (HBsAg, Anti-HCV), HIV and/or HTLV-1~History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous~History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin~History of any hematologic disorders including thromboembolic disease~History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias or related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention or treatment or a Framingham coronary disease risk prediction score of greater than 10% 10 year CHD risk~History of cerebrovascular disease, transient ischemic attack, or stroke~Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
- 2 (Type: EXPERIMENTAL): AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
- 3 (Type: EXPERIMENTAL): AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
- 4 (Type: EXPERIMENTAL): randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Computed tomography (CT) evidence of proximal PE (filling defect in at least one main or segmental pulmonary artery)~* PE symptom duration less than or equal to (\<=)14 days~* Informed consent can be obtained from participant or Legally Authorized Representative (LAR)~* Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or~* Submassive PE (RV diameter-to-LV diameter greater than or equal to \[\>=\] 0.9 on contrast-enhanced chest CT)~Exclusion Criteria:~* Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year~* Recent (within one month) or active bleeding from a major organ~* Hematocrit less than (\<) 30 percent (%)~* Platelets \< 100 thousand/microliter (mcL)~* International Normalized Ratio (INR) greater than (\>) 3~* Activated partial thromboplastin time (aPTT) \>50 seconds on no anticoagulants~* Major surgery within seven days of screening for study enrollment~* Serum creatinine \>2 milligrams/deciliter (mg/dL)~* Clinician deems high-risk for catastrophic bleeding~* History of heparin-induced thrombocytopenia (HIT)~* Pregnancy~* Catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment~* Systolic blood pressure less than 80 mm Hg despite vasopressor or inotropic support~* Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR)~* Evidence of irreversible neurological compromise~* Life expectancy \<30 days~* Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study~* Previous enrollment in the SEATTLE study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EkoSonic® Endovascular System (Type: EXPERIMENTAL): Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete